With the development of technology, a great many targeted drugs (BCL2 inhibitor, the histone deacetylas inhibitor, immunmodulator lenalidomide, obinutuzumab, phosphatidylinositol 3-kinase inhibitor, etc.)emerge and benefit B-cell lymphoma patients. This evidence concerns the gene BCL2 and B-cell non-Hodgkin lymphoma.